Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 17/20 | 0.75 |
| ▸ | PDE1A | P54750 | 5/20 | 0.62 |
| ▸ | PDE1B | Q01064 | 5/20 | 0.62 |
| ▸ | PDE1C | Q14123 | 5/20 | 0.62 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.62 |
| ▸ | PDE6A | P16499 | 3/20 | 0.61 |
| ▸ | PDE2A | O00408 | 2/20 | 0.61 |
| ▸ | PDE6D | O43924 | 2/20 | 0.61 |
| ▸ | PDE9A | O76083 | 2/20 | 0.61 |
| ▸ | PDE6G | P18545 | 2/20 | 0.61 |
| ▸ | PDE4A | P27815 | 2/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.61 |
| ▸ | PDE6B | P35913 | 2/20 | 0.61 |
| ▸ | PDE6C | P51160 | 2/20 | 0.61 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.61 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.61 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5307 | 0.90 | PDE5A (0.75) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL29655362 | 0.90 | PDE5A (0.75) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL12823115 | 0.86 | PDE5A (0.68) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL5530 | 0.86 | PDE5A (1.00) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL5901960 | 0.85 | PDE5A (0.65) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL13435578 | 0.85 | PDE5A (0.67) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL973382 | 0.85 | PDE5A (0.67) | PDE5APDE1APDE1BPDE1CPDE4B | |
| Hydrochloric Acid SCHEMBL974740 | 0.85 | PDE5A (0.98) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL12823795 | 0.85 | PDE5A (0.67) | PDE5APDE1APDE1BPDE1CPDE4B | |
| SCHEMBL14199034 | 0.85 | PDE5A (0.87) | PDE5APDE1APDE1BPDE1CPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130059844-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2013-03-07 | — | — | US | disclosed |
| US-20130059844-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2013-03-07 | — | — | US | disclosed |
| US-20130059844-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2013-03-07 | — | — | US | disclosed |
| EP-2295436-A1 | 2-Phenyl-subsitituted Imidazotriazinones as Phosphodiesterase V inhibitors | Bayer Schering Pharma AG (DE) | 2011-03-16 | — | — | EP | disclosed |
| US-20110009367-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-13 | — | — | US | disclosed |
| US-20110009367-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-13 | — | — | US | disclosed |
| US-7704999-B2 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-27 | — | — | US | disclosed |
| US-7704999-B2 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-27 | — | — | US | disclosed |
| US-7696206-B2 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-13 | — | — | US | disclosed |
| US-7696206-B2 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-13 | — | — | US | disclosed |
| US-20060189615-A1 | 2-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 2006-08-24 | — | — | US | disclosed |
| US-6890922-B2 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | BAYER HEALTHCARE AG (DE) | 2005-05-10 | — | — | US | disclosed |
| US-20050070541-A1 | 2-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 2005-03-31 | — | — | US | disclosed |
| US-20040067945-A1 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2004-04-08 | — | — | US | disclosed |
| US-6566360-B1 | Administering 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position for therapy of hypertrophy of the prostate, incontinence or female sexual dysfunction in mammals | BAYER AKTIENGESELLSCHAFT (DE) | 2003-05-20 | — | — | US | disclosed |
| US-6362178-B1 | TREATMENT OF CARDIOVASCULAR DIORDERS, CEREBROVASCULAR DISORDERS, UROGENITAL DISORDERS AND ERECTILE DYSFUNCTION | BAYER AKTIENGESELLSCHAFT (DE) | 2002-03-26 | — | — | US | disclosed |
| EP-1049695-B1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | BAYER AG (DE) | 2002-02-13 | — | — | EP | disclosed |
| EP-1174431-A2 | 2-Phenyl-substituited Imidazotriazinones as Phoshodiesterase Inhibitors | Bayer Aktiengesellschaft (DE) | 2002-01-23 | — | — | EP | disclosed |
| EP-1049695-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | BAYER AG (DE) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999024433-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009367-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE3A, PDE2A | PDE5A 4/4885PDE1A 25/4885PDE1B 14/4885 |
| US-20130059844-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE3A, PDE2A | PDE5A 4/4885PDE1A 25/4885PDE1B 14/4885 |
| US-20050070541-A1 | 2-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | PDE3B, PDE3A, PDE2A | PDE5A 4/4885PDE1A 25/4885PDE1B 14/4885 |
| US-20060189615-A1 | 2-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | PDE3B, PDE3A, PDE2A | PDE5A 4/4885PDE1A 25/4885PDE1B 14/4885 |
| US-20040067945-A1 | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors | PDE3B, PDE3A, PDE2A | PDE5A 4/4885PDE1A 25/4885PDE1B 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.